Lucile Garnero

Lucile Garnero has a diverse work experience in the field of bioscience and pharmaceutical research. Lucile began their career as an R&D intern at OZ Biosciences, where they focused on the development of transfection reagents. Lucile then worked as a summer job intern at ArcelorMittal in 2013 and 2014. In 2016, they joined Glenmark Pharmaceuticals as a Master's degree intern, where they were responsible for phage display affinity maturation of a therapeutic antibody.

After completing their Master's degree internship, Lucile worked as a Research Assistant at iTeos Therapeutics SA, where they specialized in designing targeted immunotherapies for cancer treatment. During their time there, they developed assays for pre-clinical and clinical studies in the immuno-oncology field.

In 2019, Lucile joined Confo Therapeutics as a Research Associate. Their responsibilities included developing therapeutic antibodies for severe and rare untreated diseases, as well as an alternative display platform for selecting Nbs targeting GPCRs. Lucile also conducted phenotypic single cell sorting experiments using FACS Aria III.

Most recently, Lucile has been working as a Research Assistant at Light Chain Bioscience | Novimmune SA, where their role involves assisting in various research projects.

Overall, Lucile Garnero has gained experience in antibody engineering, assay development, and immunotherapy research through their various roles in different companies.

Lucile Garnero pursued their education at ENSTBB Bordeaux INP from the year 2014 to 2017. During this time, they focused on Biotechnology and obtained a Master's degree in the field. Prior to their studies at ENSTBB Bordeaux INP, Lucile was enrolled at Université de Bordeaux from 2012 to 2014. Here, they explored a range of subjects including Biology, Chemistry, Physics, and Maths, without obtaining a specific degree. In addition to their academic pursuits, Lucile also obtained a certification in the International English Language Testing System (IELTS) from the British Council in May 2016.